{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:26:30Z","timestamp":1770506790869,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ijid.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T01:05:43Z","timestamp":1414631143000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections"],"prefix":"10.1016","volume":"30","author":[{"given":"William","family":"O\u2019Riordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purvi","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Manos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Cammarata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2014.10.009_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: the first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-144-5-200603070-00014","article-title":"The growing menace of community-acquired methicillin-resistant Staphylococcus aureus","volume":"144","author":"Moellering","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2014.10.009_bib0015","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1086\/533593","article-title":"Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.10.009_bib0020","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.10.009_bib0025","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.10.009_bib0030","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0035","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms","volume":"48","author":"Almer","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0050","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.10.009_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent","volume":"28","author":"Doan","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2014.10.009_bib0060","first-page":"S518","article-title":"Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections","volume":"15","author":"O\u2019Riordan","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2014.10.009_bib0065","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document M7-A7","year":"2006"},{"key":"10.1016\/j.ijid.2014.10.009_bib0070","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard\u2014seventh edition. CLSI document M11-A7","year":"2007"},{"key":"10.1016\/j.ijid.2014.10.009_bib0075","series-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline\u2014second edition. CLSI document M45-A2","year":"2006"},{"key":"10.1016\/j.ijid.2014.10.009_bib0080","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1128\/JCM.44.3.1141-1144.2006","article-title":"Novel multiplex PCR assay for detection of the staphylococcal virulence marker Panton\u2013Valentine leukocidin genes and simultaneous discrimination of methicillin-susceptible from -resistant staphylococci","volume":"44","author":"McClure","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2014.10.009_bib0085","series-title":"Molecular cloning: a laboratory manual","author":"Green","year":"2012"},{"key":"10.1016\/j.ijid.2014.10.009_bib0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus U.S.A. 300 clone as the predominant cause of skin and soft-tissue infections","volume":"144","author":"King","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2014.10.009_bib0095","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2014.10.009_bib0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/600294","article-title":"Severe dysglycemia with the fluoroquinolones: a class effect?","volume":"49","author":"Aspinall","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.10.009_bib0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1086\/496929","article-title":"Glucose homeostasis abnormalities associated with use of gatifloxacin","volume":"41","author":"Frothingham","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.10.009_bib0110","unstructured":"US Food and Drug Administration. Guidance for industry. Uncomplicated and complicated skin and skin structure infections\u2014developing antimicrobial drugs for treatment. FDA; 1998. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/2566dft.pdf (accessed January 22, 2014)."},{"key":"10.1016\/j.ijid.2014.10.009_bib0115","unstructured":"US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. FDA; 2013. Available at: http:\/\/www.fda.gov\/Downloads\/Drugs\/Guidancecomplianceregulatoryinformation\/Guidances\/Ucm071185.pdf (accessed January 17, 2014)."},{"key":"10.1016\/j.ijid.2014.10.009_bib0120","series-title":"Program and abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)","article-title":"Results of a phase 2 study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI). Abstract L1-1663","author":"Longcor","year":"2012"},{"key":"10.1016\/j.ijid.2014.10.009_bib0125","series-title":"Program and abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco)","article-title":"Objective measures of clinical efficacy in a phase 2b exploratory study of delafloxacin compared to vancomycin and linezolid in adults with acute bacterial skin and skin structure infections (ABSSSI). Abstract L1-1667c","author":"Longcor","year":"2012"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214016555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214016555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:23:41Z","timestamp":1538094221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971214016555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"alternative-id":["S1201971214016555"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2014.10.009","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}